Nasdaq:US$18.39 (+1.45) | HKEX:HK$28.35 (+1.45) | AIM:£2.90 (+0.14)
搜索
搜索結果
上一篇文章   |   下一篇文章
公告及新聞稿, 腫瘤學 / 免疫學 | 2007-11-22

Chi-Med Plans to Initiate Global Phase IIb Trials of its Lead Anti-Inflammatory Drug Candidate, HMPL-004, in Ulcerative Colitis Patients